Company intelligence
BrainEver
About BrainEver
BrainEver is a biopharmaceutical company developing a pipeline of novel therapies for patients with age-related neurodegenerative diseases, such as Charcot disease, Parkinson’s, and glaucoma, the second leading cause of blindness. Our mission is to develop recombinant human Homeoproteins (HPs) to halt disease progression by stopping neuronal loss and durably restoring the physiology and metabolism of the remaining neurons. BrainEver was co-founded by Bernard Gilly (iBionext) and Alain Prochiantz (Collège de France). Our innovative therapeutic approach stems from the pioneering work of Alain Prochiantz and his team on brain development and physiology. Our lead project, BREN02, focuses on developing recombinant human Engrailed-1 (hEN1) for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS). Building on the highly promising results of our preclinical studies, we are preparing to launch clinical trials by 2025. Follow us!
Verified activity
Signals from BrainEver
3 published signals
Research & Knowledge
BrainEver announced that its candidate medication Engrailed-1 is entering clinical trials to open a new therapeutic route for neurodegenerative diseases.
Reported by BrainEver
Research & Knowledge
BrainEver published a collaborative work featured on the cover of The FEBS Journal alongside Umut and other contributors.
Reported by Stephanie Vargas Abonce
Research & Knowledge
BrainEver published a proof-of-concept experiment in mice showing that muscle implants made from stem cells can mimic some benefits of exercise.
Reported by Stephanie Vargas Abonce